IE
RXRX icon

Israel Englander’s Recursion Pharmaceuticals RXRX Stock Holding History

Israel Englander’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,700
Closed -$209K – 6401
2024
Q3 		$209K Sell
31,700
-68,300
-68% -$490K ﹤0.01% 5425
2024
Q2 		$750K Buy
100,000
+58,700
+142% +$512K ﹤0.01% 4319
2024
Q1 		$412K Buy
+41,300
New +$460K ﹤0.01% 4935
2022
Q1 		– Sell
-60,000
Closed -$1.03M – 7404
2021
Q4 		$1.03M Buy
+60,000
New +$1.13M ﹤0.01% 4381

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Israel Englander's RXRX Position: Q2 2026 in Review

Israel Englander reduced its Recursion Pharmaceuticals (RXRX) stake by 30% in Q2 2026, selling an estimated $2.59M and leaving 1,834,762 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Israel Englander first reported a position in RXRX in Q4 2021 and has held it in 15 quarters since. The position peaked at $8.02M in Q1 2026. 339 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Israel Englander held 1,834,762 shares of Recursion Pharmaceuticals worth $6.73M as of Q2 2026.
  • Israel Englander sold 777,515 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.59M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2707 holding.
  • Israel Englander first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Israel Englander's Recursion Pharmaceuticals position peaked at $8.02M in Q1 2026.
  • 339 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.